3 state legislative battles to watch in 2019
Here are three states where you can expect the most substantial drug-pricing changes to be considered in 2019 — and the most pharma lobbying in response.
As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here.
WASHINGTON — Drug pricing is on the agenda here in 2019. But with Republicans controlling the Senate and Democrats controlling the House — and neither party fully on board with the White House’s work on drug pricing — the
